This 2010 review explores the role of progesterone in bone health, emphasizing its contribution to bone formation and maintenance in women. Progesterone stimulates osteoblast differentiation and, alongside estrogen, helps regulate bone remodeling. The article highlights that cyclic progestin therapy can prevent bone loss in premenopausal women with amenorrhea or subclinical
This review article explores how genetic variations affect choline metabolism and dietary requirements. It highlights that men and postmenopausal women are more likely to experience liver or muscle dysfunction when deprived of dietary choline, while premenopausal women may resist choline deficiency due to estrogen-induced expression of the PEMT gene, which
This randomized controlled trial evaluated the safety and effectiveness of a testosterone metered-dose transdermal spray in premenopausal women aged 35–46 with decreased sexual satisfaction and low serum-free testosterone levels. A daily dose of 90-μL significantly increased satisfactory sexual events compared to placebo (2.48 vs. 1.70 events, p=0.04). The most common
This review explores the neurobiological mechanisms of bremelanotide, a melanocortin receptor (MCR) agonist, in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide activates MC4Rs in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release and enhancing sexual desire. The review discusses how neurotransmitters like norepinephrine and
Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea
Two phase 3 randomized, double-blind, placebo-controlled trials evaluated the safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The trials included 1,267 participants, primarily white and U.S.-based, who received a 1.75 mg subcutaneous injection as needed before sexual activity. Bremelanotide
Bremelanotide, a melanocortin receptor agonist, has been FDA-approved as an as-needed treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low libido, though the overall clinical benefit was considered modest. Administered via subcutaneous injection
This observational study examined the effects of testosterone therapy compared to other factors on self-reported sexual satisfaction in premenopausal women. While testosterone therapy was found to influence libido and sexual function, other factors such as psychological well-being, relationship quality, and lifestyle choices played significant roles in determining overall sexual satisfaction.
This study evaluated the long-term safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. A total of 684 participants completed a 24-week double-blind core phase before entering a 52-week open-label extension. Improvements in sexual desire were sustained, with FSFI-desire scores
In the study “Women with low libido: correlation of decreased androgen levels with female sexual function index” (Int J Impot Res, 2005, PMID: 15592425), researchers investigated the relationship between androgen levels and sexual function in women with low libido compared to age-matched controls. The study included 20 premenopausal and 20
